The Challenges for Biosimilars in the EU
This article was originally published in SRA
The regulatory framework for biosimilar medicines in the European Union is working and delivering products. Once approved, however, the products are not penetrating the market as quickly as generics firms had hoped. This was one of the key messages to emerge from the 7th European Generic medicines Association Annual Symposium on Biosimilar Medicines in London on 23-24 April.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.